CORX Stock UPDATES Cortex Pharm Inc (CORX) 0.0410 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cortex Pharm Inc (CORX) 0.0410 $CORX

Cortex Pharmaceuticals, Inc. Enters Into New License Agreement With the University of Illinois Granting Cortex Patent Rights to the Use of Cannabinoids for the Treatment of Sleep Related Breathing Disorders
GlobeNewswire - Tue Jul 01, 4:30AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a biopharmaceutical company currently engaged in the development of drugs for respiratory disorders, announced today that it has entered into a new license agreement with the University of Illinois that provides Cortex with exclusive rights to patents claiming the use of cannabinoids for the treatment of sleep related breathing disorders. Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea.

Respiratory Depression - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r3lqgf/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Respiratory Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r3...espiratory

Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntingtons Disease Therapeutics - 2013 Global Strategic Business Report
M2 - Fri Aug 02, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnkpxr/huntingtons#summary) has announced the addition of the "Huntingtons Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntingtons Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Hd Therapeutics Market Trends 3. Hd Research And Drug Pipeline 4. Research Breakthroughs In Hd Arena 5. An Overview Of Huntington's Disease 6. Clinical Trials 7. Recent Industry Activity 8. Corporate Activity In The Recent Past - A Perspective Builder 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Europe 3. Rest Of World IV. Competitive Landscape Companies Mentioned The report profiles 35 companies including - Alnylam Pharmaceuticals - AmpliPhi Biosciences Corp. - Ceregene - Cortex Pharmaceuticals - Intellect Neurosciences Incorporation - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - Teva Pharmaceutical Industries Ltd. - Trophos SA - Valeant Pharmaceuticals International - Vertex Pharmaceuticals Incorporated. For more information, including full list of companies profiled, please visit http://www.researchandmarkets.com/research/tn...ns#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Sleep Apnea - Pipeline Review, H1 2013
M2 - Mon Jun 17, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6fqjfg/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2013" report to their offering. 'Sleep Apnea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for sleep apnea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for sleep apnea. Scope - A snapshot of the global therapeutic scenario for Sleep Apnea. - A review of the Sleep Apnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sl

Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio

Fragile X Syndrome - Pipeline Review, H2 2012 Report Reviews Key Players Involved In the Therapeutic Development for Fragile X Syndrome
M2 - Mon Dec 17, 9:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/rck2wt/fragile_x) has announced the addition of Global Markets Direct's new report "Fragile X Syndrome - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Fragile X Syndrome - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Fragile X Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global thera




Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 57

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 71

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 93

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 147

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading

Top 5 Most Recently Viewed Articles

Surge in Gold Prices Reflects Political and Economic Tensions

Updated Category News Views 283

Gold Prices Reach New Heights Amid Political Turmoil Gold prices have reached unprecedented levels recently, reflecting a surge in safe-haven demand driven by rising political uncertainties in key regions like the U.S. and Japan. As concerns about potential economic instability grow, this precious metal has emerged as a popular choice for investors looking to protect...

Continue Reading
BlackSky Secures Navy Contract to Enhance Satellite Imaging

Updated Category News Views 222

Alright, here’s the scoop: BlackSky Technology Inc. just bagged a major contract with the U.S. Navy, and it’s all about beefing up their Gen-3 imaging satellites. Now, why does this matter? This initiative is a piece of the broader Project Overmatch—a military strategy designed to supercharge the Joint All Domain Command and Control (JADC2) mission. What’s at...

Continue Reading
Discover the Innovative FINGER GRIP for Enhanced Sports Performance

Updated Category News Views 217

Enhancing Sports with the Innovative FINGER GRIP In the dynamic world of sports, having the right equipment can make all the difference. An inventive mind from Pittsburgh has introduced an innovative product, the FINGER GRIP, aimed at elevating performance in games like pickleball and tennis. This new grip is revolutionizing how athletes interact with their paddles and...

Continue Reading
Updated Voting Shares of AB Volvo: Significant Changes

Updated Category News Views 215

Changes in AB Volvo's Voting Shares AB Volvo has recently undergone an important transformation affecting its voting shares. The conversion of 175,000 Series A shares into Series B shares is a key development for the company. This conversion stems from a provision accepted at the 2011 Annual General Meeting, allowing Series A shareholders to switch their shares to Series...

Continue Reading
Warner Bros. Discovery's Q4: Strong Revenue Growth & Future Plans

Updated Category News Views 324

Warner Bros. Discovery Reports Impressive Q4 Results In a recent financial assessment, Warner Bros. Discovery, Inc (NASDAQ: WBD) unveiled its latest quarterly performance, showcasing a fiscal fourth-quarter revenue of $10.03 billion. Although this represented a slight 1% ex-FX decline compared to the previous year, it was just shy of analysts' expectations of $10.19...

Continue Reading